Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
SPRB Stock Chart & Stats
$54.20
--
Market closed
$54.20
--
Day’s Range― - ―
52-Week Range$4.32 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$58.02M
Enterprise Value$21.17M
Total Cash (Recent Filing)$10.67M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta-10.92
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.58
Shares Outstanding1,070,370
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.59
Price to Sales (P/S)3.44
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue30.38
Enterprise Value/Gross Profit30.38
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$241.50Price Target Upside345.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-31.01
Revenue Forecast (FY)$3.59M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Biomarker SupportExtended clinical data showed normalization of a cerebrospinal fluid biomarker alongside stabilization of cognitive measures and organ sizes with treatment, supporting a favorable benefit profile.
Non-dilutive Financing PotentialExisting capital, a committed venture debt facility, and restored eligibility to receive and sell a Priority Review Voucher create potential non-dilutive funding that can ease financing pressure.
Regulatory Pathway ClarityFDA feedback indicated integrated clinical and natural history data together with a cerebrospinal fluid biomarker could support an accelerated approval pathway, reducing regulatory uncertainty.
Bears Say
Funding Need From Timeline RevisionRevision to the filing timeline increases the likelihood that additional funding will be required to support operations through approval and market entry, elevating dilution risk and execution uncertainty.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.32 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $58.02M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is May 13, 2026 which is in 71 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Nov 10, 2025. The company reported -$14.58 earnings per share for the quarter, missing the consensus estimate of -$13.935 by -$0.645.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 1,070,370 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$14.58 in its last earnings report, missing expectations of -$13.935. Following the earnings report the stock price went down -2.552%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$241.50 (345.57% Upside)
$241.50 (345.57% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-167.93%
Trailing 12-Months
Asset Growth
-71.11%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$241.50
▲(345.57% Upside)